Table 2 |
||
|
Gene sets used in this analysis |
||
| Functional Pathway |
Number of probe sets (corresponding # of known genes) |
Reference |
|
|
||
| Cytogenetic sets (n = 319 sets) |
15-500 (variable) |
Subramanian et al. [5] |
|
|
||
| Functional sets (n = 522 sets) |
15-500 (variable) |
Subramanian et al. [5] |
|
|
||
| Oncogenic Pathways (5 sets) |
Bild et al. [10] |
|
| Myc |
164 (139) |
|
| Ras |
228 (176) |
|
| E2F3 |
173 (147) |
|
| β-catenin |
54 (42) |
|
| Src |
46 (44) |
|
|
|
||
| Genomic Grade Index (1 set) |
242 (183) |
Sotiriou et al. [13] |
|
|
||
| 76-gene prognostic signature (1 set) |
76 (76) |
Wang et al. [14] |
|
|
||
| Proliferation signature (1 set) |
74 (44) |
Whitfield et al. [15] |
|
|
||
| ABC transporter gene set (1 set) |
61 (47) |
Szakacs et al. [16] |
|
|
||
| Mutant-p53 signature (1 set) |
25 (21) |
Miller et al. [11] |
|
|
||
| ER-associated gene set (1 set) |
200 (187) |
Symmans et al. [12] |
|
|
||
|
Tordai et al. Breast Cancer Research 2008 10:R37 doi:10.1186/bcr2088 |
||
